Lantheus Holdings Inc (LNTH) - Total Liabilities
Based on the latest financial reports, Lantheus Holdings Inc (LNTH) has total liabilities worth $1.14 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Lantheus Holdings Inc (LNTH) cash flow conversion to assess how effectively this company generates cash.
Lantheus Holdings Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Lantheus Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Check LNTH asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Lantheus Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Lantheus Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ChampionX Corporation
NASDAQ:CHX
|
USA | $1.60 Billion |
|
Teleflex Incorporated
NYSE:TFX
|
USA | $3.82 Billion |
|
Sonoco Products Company
NYSE:SON
|
USA | $8.40 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $33.25 Million |
|
Outfront Media Inc
NYSE:OUT
|
USA | $4.58 Billion |
|
Hess Midstream Partners LP
NYSE:HESM
|
USA | $4.01 Billion |
|
Cochin Shipyard Limited
NSE:COCHINSHIP
|
India | Rs85.55 Billion |
|
Sectra AB (publ)
ST:SECT-B
|
Sweden | Skr1.71 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Lantheus Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Lantheus Holdings Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lantheus Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lantheus Holdings Inc (2012–2025)
The table below shows the annual total liabilities of Lantheus Holdings Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.14 Billion | +27.49% |
| 2024-12-31 | $892.33 Million | +6.83% |
| 2023-12-31 | $835.26 Million | -4.44% |
| 2022-12-31 | $874.11 Million | +118.89% |
| 2021-12-31 | $399.35 Million | +12.30% |
| 2020-12-31 | $355.62 Million | +22.07% |
| 2019-12-31 | $291.32 Million | -21.02% |
| 2018-12-31 | $368.83 Million | +2.29% |
| 2017-12-31 | $360.57 Million | -0.51% |
| 2016-12-31 | $362.41 Million | -15.26% |
| 2015-12-31 | $427.67 Million | -12.51% |
| 2014-12-31 | $488.84 Million | -1.61% |
| 2013-12-31 | $496.83 Million | -0.19% |
| 2012-12-31 | $497.76 Million | -- |
About Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceut… Read more